World Bank. World Development Report 1993: Investing in Health. Online https://openknowledge.worldbank.org/handle/10986/5976 (Accessed May 2022)

Murray CJ. Quantifying the burden of disease: the technical basis for disability-adjusted life years. Bull World Health Organ. 1994;72(3):429-445. PMID:8062401

Devleesschauwer B, Havelaar AH, Maertens de Noordhout C, et al. Calculating disability-adjusted life years to quantify burden of disease. Int J Public Health. 2014;59(3):565-569. https://doi.org/10.1007/s00038-014-0552-z PMID:24752429

Essink-Bot ML, Bonsel G. How to derive disability weights (Chapter 9.1). J Immunol. 2002;01(01):449-465.

Murray CJL, Lopez AD; World Health Organization, World Bank & Harvard School of Public Health. (‎1996)‎. The global burden of disease: a comprehensive assessment of mortality and disability from diseases, injuries, and risk factors in 1990 and projected to 2020: summary/edited by Christopher J. L. Murray, Alan D. Lopez. World Health Organization. Online https://apps.who.int/iris/handle/10665/41864 (Accessed May 2022).

Haagsma JA, Polinder S, Cassini A, Colzani E, Havelaar AH. Review of disability weight studies: comparison of methodological choices and values. Popul Health Metr. 2014;12(1):20. https://doi.org/10.1186/s12963-014-0020-2 PMID:26019690

Ock M, Park B, Park H, et al. Disability weights measurement for 289 causes of disease considering disease severity in Korea. J Korean Med Sci. 2019;34(suppl 1):e60. https://doi.org/10.3346/jkms.2019.34.e60 PMID:30923484

Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394-424. https://doi.org/10.3322/caac.21492 PMID:30207593

AIOM-AIRTUM. The numbers of cancer in Italy. 2019 [in Italian]. Online https://www.aiom.it/i-numeri-del-cancro-in-italia/ (Accessed May 2022).

Saad F, Hotte SJ. Guidelines for the management of castrate-resistant prostate cancer. Can Urol Assoc J. 2010;4(6):380-384. https://doi.org/10.5489/cuaj.10167 PMID:21191494

Hotte SJ, Saad F. Current management of castrate-resistant prostate cancer. Curr Oncol. 2010;17(12)(suppl 2):S72-S79. https://doi.org/10.3747/co.v17i0.718 PMID:20882137

Xie W, Regan MM, Buyse M, et al; ICECaP Working Group. Metastasis-free survival is a strong surrogate of overall survival in localized prostate cancer. J Clin Oncol. 2017;35(27):3097-3104. https://doi.org/10.1200/JCO.2017.73.9987 PMID:28796587

Halabi S, Kelly WK, Ma H, et al. Meta-analysis evaluating the impact of site of metastasis on overall survival in men with castration-resistant prostate cancer. J Clin Oncol. 2016;34(14):1652-1659. https://doi.org/10.1200/JCO.2015.65.7270 PMID:26951312

López-Campos F, Conde-Moreno A, Barrado Los Arcos M, Gómez-Caamaño A, García-Gómez R, Hervás Morón A. treatment landscape of nonmetastatic castration-resistant prostate cancer: a window of opportunity. J Pers Med. 2021;11(11):1190. https://doi.org/10.3390/jpm11111190 PMID:34834544

Mateo J, Fizazi K, Gillessen S, et al. Managing nonmetastatic castration-resistant prostate cancer. Eur Urol. 2019 Feb;75(2):285-293. https://doi.org/10.1016/j.eururo.2018.07.035 PMID:30119986

Fitzmaurice C, Abate D, Abbasi N, et al; Global Burden of Disease Cancer Collaboration. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer groups, 1990 to 2017: a systematic analysis for the global burden of disease study. JAMA Oncol. 2019;5(12):1749-1768. https://doi.org/10.1001/jamaoncol.2019.2996 PMID:31560378

Haagsma JA, Maertens de Noordhout C, Polinder S, et al. Assessing disability weights based on the responses of 30,660 people from four European countries. Popul Health Metr. 2015;13(1):10. https://doi.org/10.1186/s12963-015-0042-4 PMID:26778920

World Medical Association. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2013;310(20):2191-2194. https://doi.org/10.1001/jama.2013.281053 PMID:24141714

Lohr SL. Sampling. Design and analysis. 3rd ed. CRC Press/Chapman & Hall; 2022.

Creswell JW, Poth CN. Qualitative inquiry and research design: choosing among five approaches. SAGE Publications; 2016.

Castleberry A, Nolen A. Thematic analysis of qualitative research data: is it as easy as it sounds? Curr Pharm Teach Learn. 2018;10(6):807-815. https://doi.org/10.1016/j.cptl.2018.03.019PMID:30025784

Scher HI, Solo K, Valant J, Todd MB, Mehra M. Prevalence of prostate cancer clinical states and mortality in the United States: estimates using a dynamic progression model. PLoS One. 2015;10(10):e0139440. https://doi.org/10.1371/journal.pone.0139440 PMID:26460686

Stouthard M, Essink-Bot M-L, Bonsel G, et al. Disability weights for diseases in The Netherlands. Tijdschr Gerontol Geriatr. 1997;01(01).

Schwarzinger M, Stouthard ME, Burström K, Nord E. Cross-national agreement on disability weights: the European Disability Weights Project. Popul Health Metr. 2003;1(1):9. https://doi.org/10.1186/1478-7954-1-9 PMID:14633276

Haagsma JA, Havelaar AH, Janssen BM, Bonsel GJ. Disability adjusted life years and minimal disease: application of a preference-based relevance criterion to rank enteric pathogens. Popul Health Metr. 2008;6(1):7. https://doi.org/10.1186/1478-7954-6-7 PMID:19114007

EuroQol Group. EuroQol—a new facility for the measurement of health-related quality of life. Health Policy. 1990;16(3):199-208. https://doi.org/10.1016/0168-8510(90)90421-9PMID:10109801

Lloyd AJ, Kerr C, Penton J, Knerer G. Health-related quality of life and health utilities in metastatic castrate-resistant prostate cancer: a survey capturing experiences from a diverse sample of UK patients. Value Health. 2015;18(8):1152-1157. https://doi.org/10.1016/j.jval.2015.08.012 PMID:26686802

Nord E. The person-trade-off approach to valuing health care programs. Med Decis Making. 1995;15(3):201-208. https://doi.org/10.1177/0272989X9501500302 PMID:7564933

van Spijker BA, van Straten A, Kerkhof AJ, Hoeymans N, Smit F. Disability weights for suicidal thoughts and non-fatal suicide attempts. J Affect Disord. 2011 Nov;134(1-3):341-347. https://doi.org/10.1016/j.jad.2011.05.020 PMID.21652085

Froberg DG, Kane RL. Methodology for measuring health-state preferences—I: measurement strategies. J Clin Epidemiol. 1989;42(4):345-354. https://doi.org/10.1016/0895-4356(89)90039-5PMID:2723695

Little RJ, Carpenter JR, Lee KJ. A comparison of three popular methods for handling missing data: complete-case analysis, inverse probability weighting, and multiple imputation. Sociol Methods Res. 2022. https://doi.org/10.1177/00491241221113873

Kendall MG. A new measure of rank correlation. Biometrika. 1938;30(1/2):81-93. https://doi.org/10.2307/2332226

Salomon JA, Haagsma JA, Davis A, et al. Disability weights for the Global Burden of Disease 2013 study. Lancet Glob Health. 2015;3(11):e712-e723. https://doi.org/10.1016/S2214-109X(15)00069-8 PMID:26475018

Associazione Italiana di Oncologia Medica (AIOM). Guidelines – Prostate cancer. 2019 [in Italian]. Online https://www.aiom.it/linee-guida-aiom-carcinoma-della-prostata-2019/ (Accessed May 2022).

Tartarone A, Lerose R, Tartarone M. Decisions and dilemmas in non-metastatic castration-resistant prostate cancer management. Med Oncol. 2022;39(7):107. https://doi.org/10.1007/s12032-022-01743-7 PMID:35553247

Cattrini C, Caffo O, De Giorgi U, et al. Apalutamide, darolutamide and enzalutamide for nonmetastatic castration-resistant prostate cancer (nmCRPC): a critical review. Cancers (Basel). 2022;14(7):1792. https://doi.org/10.3390/cancers14071792 PMID:35406564

Brazier J, Deverill M, Green C. A review of the use of health status measures in economic evaluation. J Health Serv Res Policy. 1999;4(3):174-184. https://doi.org/10.1177/135581969900400310 PMID:10538884

Allison PD. Missing data. Sage Publications; 2002. https://doi.org/10.4135/9781412985079

Little RJ, Rubin DB. Statistical analysis with missing data. John Wiley & Sons; 2020.